Evotec OAI AG and Rib-X Pharmaceuticals, Inc., announced the formation of a medicinal chemistry partnership.
Scientists from Rib-X and Evotec OAI will collaborate on several research programmes. Evotec OAI will be utilising its state-of-the-art integrated medicinal chemistry and parallel synthesis platform to facilitate Rib-X's efforts to identify novel antibiotics for clinical development.
Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling
Evotec AG announced that Evotec and Dow AgroSciences (DOW) have entered into a research collaboration with the objective of leveraging Evotec's chemical proteomics services to support compounds in development at Dow AgroSciences. To this end, Evotec will perform chemical proteomics services ... more
Evotec to realign Discovery Chemistry Operations
Evotec AG announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in ... more
Evotec AG announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. The contract covers a period of five years and has a total value of up to EUR7.7 million (approx. USD 10 million).Under the agreement Evotec, through its San Francisco ope ... more
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In a ... more
